A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.

• Status: RECRUITING
• Trial end date: 2026-07-01

Summary

This study aimed to compare the efficacy of neoadjuvant low-dose radiotherapy combined with targeted therapy and immunotherapy versus targeted therapy and immunotherapy alone in patients with resectable head and neck squamous cell carcinoma.

• Phase: PHASE2

Details

• Lead Sponsor: West China Hospital
• Treatments: Afatinib; Immunotherapy; Radiotherapy; tislelizumab